Literature DB >> 16075927

Effects of alpha-interferon on insulin-like growth factor-I, insulin-like growth factor-II and insulin-like growth factor binding protein-3 secretion by a human lung cancer cell line in vitro.

P Del Monte1, C Laurino, M Arvigo, C Palermo, F Minuto, A Barreca.   

Abstract

The aim of our study was to evaluate the effect of alpha-interferon (alpha-IFN) on cell growth and on the different IGF system components in a human non-small cell lung cancer line (Calu-6) in vitro. Our results confirm the release of IGF-I and IGF-II by these cells. The amount of IGF-II in conditioned media (10.25 +/- 3.95 nM/10(6) cells, mean +/- SE) was more than 10-fold higher than that of IGF-I. alpha-IFN treatment reduced IGF-II levels in the media, with a maximal effect between 1 and 10 U/ml (delta% of control: -31 and -55%, respectively, p < 0.05). IGF-I was significantly reduced at 0.5 U/ml (p < 0.01). No difference, however, was observed in IGF mRNA expression between untreated and alpha-IFN treated cells. An increase in IGF-I and IGF-II intracellular levels in alpha-IFN treated cultures was observed, suggesting that alpha-IFN can regulate the transfer of these peptides into the cells. Furthermore, IGF type-I and particularly type-lI receptor expression was increased after alpha-IFN treatment. IGFBP-3 was detected only in trace amounts in the conditioned media; however, it showed an increase after alpha-IFN treatment (+110% at 1 U/ml). IGFBP-3 mRNA expression showed a slight increase after treatment with 1 and 10 U/ml. alpha-IFN (1-10 U/ml) reduced the stimulatory effect of IGF-I on cell replication (p < 0.01), inhibited (p < 0.01) cell replication in untreated and in fetal calf serum (FCS)-stimulated cells, and increased apoptosis in Calu-6 cells. Our data suggest that alpha-IFN may exert its effects at the cellular level in part through modification of the local IGF system.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16075927     DOI: 10.1007/bf03347224

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  47 in total

1.  Expression of the insulin-like growth factor system and cancer progression in hormone-treated prostate cancer patients.

Authors:  K Mita; M Nakahara; T Usui
Journal:  Int J Urol       Date:  2000-09       Impact factor: 3.369

Review 2.  Genetic and immunologic therapies for lung cancer.

Authors:  Stephen G Swisher; Jack A Roth; David P Carbone
Journal:  Semin Oncol       Date:  2002-02       Impact factor: 4.929

3.  IFN-alpha2b suppresses the fibrogenic effects of insulin-like growth factor-1 in dermal fibroblasts.

Authors:  C Telasky; E E Tredget; Q Shen; M R Khorramizadeh; T Iwashina; P G Scott; A Ghahary
Journal:  J Interferon Cytokine Res       Date:  1998-08       Impact factor: 2.607

4.  Evidence for autocrine mitogenic stimulation by somatomedin-C/insulin-like growth factor I on an established human lung cancer cell line.

Authors:  F Minuto; P Del Monte; A Barreca; A Alama; G Cariola; G Giordano
Journal:  Cancer Res       Date:  1988-07-01       Impact factor: 12.701

5.  Insulin-like growth factor family and combined antisense approach in therapy of lung carcinoma.

Authors:  Jasminka Pavelić; Ljubomir Pavelić; Jerolim Karadza; Simun Krizanac; Josip Unesić; Sime Spaventi; Kresimir Pavelić
Journal:  Mol Med       Date:  2002-03       Impact factor: 6.354

6.  Induction of apoptosis by combined treatment with differentiation-inducing agents and interferon-alpha in human lung cancer cells.

Authors:  Yuri Yamamoto-Yamaguchi; Junko Okabe-Kado; Takashi Kasukabe; Yoshio Honma
Journal:  Anticancer Res       Date:  2003 May-Jun       Impact factor: 2.480

7.  Expression of insulinlike growth factor (IGF) and IGF-binding protein genes in human lung tumor cell lines.

Authors:  J G Reeve; A Brinkman; S Hughes; J Mitchell; J Schwander; N M Bleehen
Journal:  J Natl Cancer Inst       Date:  1992-04-15       Impact factor: 13.506

8.  Evidence for an increased somatomedin-C/insulin-like growth factor I content in primary human lung tumors.

Authors:  F Minuto; P Del Monte; A Barreca; P Fortini; G Cariola; G Catrambone; G Giordano
Journal:  Cancer Res       Date:  1986-02       Impact factor: 12.701

9.  Insulin-like growth factor-I can mediate autocrine proliferation of human small cell lung cancer cell lines in vitro.

Authors:  Y Nakanishi; J L Mulshine; P G Kasprzyk; R B Natale; R Maneckjee; I Avis; A M Treston; A F Gazdar; J D Minna; F Cuttitta
Journal:  J Clin Invest       Date:  1988-07       Impact factor: 14.808

10.  A dominant negative type I insulin-like growth factor receptor inhibits metastasis of human cancer cells.

Authors:  Deepali Sachdev; Julie S Hartell; Adrian V Lee; Xihong Zhang; Douglas Yee
Journal:  J Biol Chem       Date:  2003-11-13       Impact factor: 5.157

View more
  4 in total

1.  Expression and clinical significance of insulin-like growth factor 1 in lung cancer tissues and perioperative circulation from patients with non-small-cell lung cancer.

Authors:  S Fu; H Tang; Y Liao; Q Xu; C Liu; Y Deng; J Wang; J Wang; X Fu
Journal:  Curr Oncol       Date:  2016-02-18       Impact factor: 3.677

2.  Association of preoperative serum IGF- I concentration with clinicopathological parameters in patients with non-small cell lung cancer.

Authors:  Sheng-Ling Fu; He-Xiao Tang; Yong-de Liao; Wen-Yang Jiang; Qin-Zi Xu; Yu Deng; Xiang-Ning Fu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2013-04-17

3.  Effects of insulin-like growth factor 1 receptor and its inhibitor AG1024 on the progress of lung cancer.

Authors:  Yan-Hong Wei; He-Xiao Tang; Yong-de Liao; Sheng-Ling Fu; Li-Qiang Xu; Guang Chen; Chao Zhang; Sheng Ju; Zhao-Guo Liu; Liang-Kun You; Li Yu; Sheng Zhou
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2015-12-16

4.  Gene Expression Profiling Identifies Interferon Signalling Molecules and IGFBP3 in Human Degenerative Annulus Fibrosus.

Authors:  Zepur Kazezian; Rahul Gawri; Lisbet Haglund; Jean Ouellet; Fackson Mwale; Finbarr Tarrant; Peadar O'Gaora; Abhay Pandit; Mauro Alini; Sibylle Grad
Journal:  Sci Rep       Date:  2015-10-22       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.